Scandinavian ChemoTech

This vetIQure TSE system will be delivered to a highly rated emergency veterinary and specialty hospital in Dayton, Ohio, which serves more than 20,000 patients on a yearly basis.

With this installation, ChemoTech can now announce that no less than six states in the US (Florida, California, Ohio, Idaho, West Virginia and Louisiana) have the possibility to offer the Tumour Specific Electroporation™ (TSE) technology for Animal Care, a successful and less destructive alternative for treatment of pets that suffer from cancer.

"We are of course extremely pleased with the growing success and with the interest that veterinarians, clinics, and large veterinarian corporations are showing in the US, Europe, Turkey, and Australia. With this rapid pace in new orders and installations, we see our vision to establish TSE as a completely new treatment standard take a big leap towards becoming a reality", says Mohan Frick CEO for Vetiqure AB.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.

.